Holen Sie sich die Stockscreener-App
44.05
0.84%
-0.38
Handel nachbörslich:
44.05
Schlusskurs vom Vortag:
$44.43
Offen:
$44.22
24-Stunden-Volumen:
767.81K
Relative Volume:
0.56
Marktkapitalisierung:
$4.15B
Einnahmen:
$4.72M
Nettoeinkommen (Verlust:
$-277.91M
KGV:
-11.81
EPS:
-3.73
Netto-Cashflow:
$-203.56M
1W Leistung:
+3.66%
1M Leistung:
+29.57%
6M Leistung:
+47.93%
1J Leistung:
-17.03%
1-Tages-Spanne:
$43.70
$44.41
1-Wochen-Bereich:
$41.85
$46.05
52-Wochen-Spanne:
$24.10
$62.53
Crinetics Pharmaceuticals Inc Stock (CRNX) Company Profile
Firmenname
Crinetics Pharmaceuticals Inc
Sektor
Branche
Telefon
858-450-6464
Adresse
6055 LUSK BLVD., SAN DIEGO, CA
Vergleichen Sie CRNX mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CRNX
Crinetics Pharmaceuticals Inc
|
44.05 | 4.18B | 4.72M | -277.91M | -203.56M | -3.73 |
|
VRTX
Vertex Pharmaceuticals Inc
|
412.22 | 104.45B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
469.36 | 60.95B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
572.60 | 59.11B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
812.95 | 49.23B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.94 | 35.92B | 4.56B | -176.77M | 225.30M | -1.7177 |
Crinetics Pharmaceuticals Inc Stock (CRNX) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-10 | Eingeleitet | Goldman | Neutral |
| 2025-03-25 | Eingeleitet | Stifel | Buy |
| 2025-02-11 | Eingeleitet | TD Cowen | Buy |
| 2025-02-04 | Eingeleitet | Wolfe Research | Peer Perform |
| 2025-01-22 | Hochstufung | Jefferies | Hold → Buy |
| 2024-03-06 | Eingeleitet | Citigroup | Buy |
| 2024-01-16 | Eingeleitet | Morgan Stanley | Overweight |
| 2023-12-21 | Eingeleitet | Jefferies | Hold |
| 2023-11-20 | Fortgesetzt | JP Morgan | Overweight |
| 2023-10-24 | Fortgesetzt | Cantor Fitzgerald | Overweight |
| 2023-08-31 | Eingeleitet | Oppenheimer | Outperform |
| 2023-04-24 | Eingeleitet | Piper Sandler | Overweight |
| 2023-03-30 | Eingeleitet | Robert W. Baird | Outperform |
| 2021-11-30 | Eingeleitet | JMP Securities | Mkt Outperform |
| 2021-11-23 | Eingeleitet | Evercore ISI | Outperform |
| 2021-06-18 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2019-12-23 | Eingeleitet | ROTH Capital | Buy |
| 2019-02-14 | Eingeleitet | H.C. Wainwright | Buy |
| 2018-08-13 | Eingeleitet | JP Morgan | Neutral |
| 2018-08-13 | Eingeleitet | Leerink Partners | Outperform |
| 2018-08-13 | Eingeleitet | Piper Jaffray | Overweight |
Alle ansehen
Crinetics Pharmaceuticals Inc Aktie (CRNX) Neueste Nachrichten
Crinetics Pharmaceuticals Inc. stock outlook for YEAR2025 Historical Comparison & Real-Time Stock Movement Alerts - newser.com
Why Crinetics Pharmaceuticals (CRNX) Is Up 6.8% After FDA Approval of First Oral Acromegaly Therapy - Sahm
Is it time to cut losses on Crinetics Pharmaceuticals Inc.Portfolio Profit Report & High Win Rate Trade Alerts - newser.com
Will Crinetics Pharmaceuticals Inc. benefit from macro trendsQuarterly Profit Review & Proven Capital Preservation Tips - newser.com
What recovery options are there for Crinetics Pharmaceuticals Inc.2025 Institutional Moves & Fast Exit and Entry Strategy Plans - newser.com
Using data tools to time your Crinetics Pharmaceuticals Inc. exitJuly 2025 Earnings & Low Risk Entry Point Guides - newser.com
How to use a screener to detect Crinetics Pharmaceuticals Inc. breakouts2025 Technical Overview & Weekly Watchlist for Hot Stocks - newser.com
Published on: 2025-10-13 23:24:35 - newser.com
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(4) - MarketScreener
What candlestick patterns are forming on Crinetics Pharmaceuticals Inc.2025 Dividend Review & Free Community Consensus Stock Picks - newser.com
Sector ETF performance correlation with Crinetics Pharmaceuticals Inc.July 2025 Closing Moves & Low Risk Investment Opportunities - newser.com
Will Crinetics Pharmaceuticals Inc. stock keep outperforming rivalsWeekly Volume Report & High Yield Equity Trading Tips - newser.com
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
Crinetics Pharmaceuticals Announces October 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire Inc.
Is it too late to sell Crinetics Pharmaceuticals Inc.Market Trend Summary & Verified Swing Trading Watchlists - newser.com
Crinetics Pharmaceuticals' (CRNX) "Sell (D-)" Rating Reiterated at Weiss Ratings - MarketBeat
Will a bounce in Crinetics Pharmaceuticals Inc. offer an exit2025 Market Outlook & Fast Momentum Stock Entry Tips - newser.com
Crinetics stock holds Overweight rating at Piper Sandler after acromegaly drug approval - Investing.com Canada
Crinetics Pharmaceuticals’ SWOT analysis: oral endocrine drug stock poised for growth - Investing.com Nigeria
Cantor Fitzgerald Maintains a Buy Rating on Crinetics Pharmaceuticals (CRNX) - Yahoo Finance
A Look at Crinetics Pharmaceuticals's Valuation Following FDA Approval of PALSONIFY for Acromegaly - Yahoo Finance
Crinetics Pharmaceuticals (CRNX): Assessing Valuation After a 15% Share Price Climb This Month - Sahm
Crinetics Pharmaceuticals to Report Third Quarter 2025 Financial Results on November 6, 2025 - The Manila Times
Using portfolio simulators with Crinetics Pharmaceuticals Inc. includedWeekly Stock Recap & Free Expert Verified Stock Movement Alerts - newser.com
What MACD and RSI say about Crinetics Pharmaceuticals Inc.Earnings Recap Report & Capital Efficient Trade Techniques - newser.com
Does Crinetics Pharmaceuticals Inc. fit your quant trading model2025 Support & Resistance & High Yield Stock Recommendations - newser.com
Comparing Crinetics Pharmaceuticals Inc. in custom built stock radarsMarket Risk Summary & Daily Market Momentum Tracking - newser.com
Crinetics Pharmaceuticals, Inc. (NASDAQ:CRNX) Given Consensus Rating of "Moderate Buy" by Analysts - MarketBeat
Crinetics Pharmaceuticals Shares Swing After Data on Paltusotine and Valuation Metrics Scrutinized - Sahm
Insider Selling: Crinetics Pharmaceuticals (NASDAQ:CRNX) Insider Sells 5,000 Shares of Stock - MarketBeat
Crinetics Pharmaceuticals Hits Day High with 16.05% Surge in Stock Price - Markets Mojo
How analysts revise price targets for Crinetics Pharmaceuticals Inc. (6Z4) stockJuly 2025 Macro Moves & Long-Term Growth Stock Strategies - newser.com
Crinetics Pharmaceuticals Inc. stock chart pattern explainedJuly 2025 Momentum & Accurate Entry and Exit Point Alerts - newser.com
Crinetics Pharmaceuticals (NASDAQ:CRNX) Director Matthew Fust Sells 16,000 Shares - MarketBeat
Oppenheimer Raises Price Target on CRNX to $87, Maintains Outper - GuruFocus
Crinetics Pharmaceuticals (CRNX) Price Target Increased by 11.63% to 81.09 - Nasdaq
JMP Backs Crinetics Pharmaceuticals, Inc. (CRNX) With Big Upside Post-Approval - MSN
Oppenheimer Raises Price Target on CRNX to $87, Maintains Outperform Rating | CRNX Stock News - GuruFocus
Crinetics Pharmaceuticals Opens with 14.43% Gain, Surpassing S&P 500's 0.59% Rise - Markets Mojo
Crinetics Pharmaceuticals Inc 6Z4 Stock Analysis and ForecastQuarterly Earnings Review & Small Investment Capital Tips - earlytimes.in
Crinetics Pharmaceuticals (NASDAQ:CRNX) Price Target Raised to $87.00 at Oppenheimer - MarketBeat
Finanzdaten der Crinetics Pharmaceuticals Inc-Aktie (CRNX)
Umsatz
Nettogewinn
Free Cashflow
ENV
Crinetics Pharmaceuticals Inc-Aktie (CRNX) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Pizzuti Dana | Chief Med and Dev Officer |
Oct 01 '25 |
Sale |
41.81 |
5,000 |
209,050 |
66,270 |
5.47%
1.59%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):